CA2326804A1 - Compounds with activity on muscarinic receptors - Google Patents

Compounds with activity on muscarinic receptors Download PDF

Info

Publication number
CA2326804A1
CA2326804A1 CA002326804A CA2326804A CA2326804A1 CA 2326804 A1 CA2326804 A1 CA 2326804A1 CA 002326804 A CA002326804 A CA 002326804A CA 2326804 A CA2326804 A CA 2326804A CA 2326804 A1 CA2326804 A1 CA 2326804A1
Authority
CA
Canada
Prior art keywords
compounds
activity
muscarinic receptors
muscarinic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002326804A
Other languages
French (fr)
Other versions
CA2326804C (en
Inventor
Mark Robert Brann
Terri Messier
Erika Anne Currier
Katharan Lauri Duggento
Mikael Friberg
Niels Skjaerbaek
Tracy Spalding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc.
Mark Robert Brann
Terri Messier
Erika Anne Currier
Katharan Lauri Duggento
Mikael Friberg
Niels Skjaerbaek
Tracy Spalding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc., Mark Robert Brann, Terri Messier, Erika Anne Currier, Katharan Lauri Duggento, Mikael Friberg, Niels Skjaerbaek, Tracy Spalding filed Critical Acadia Pharmaceuticals Inc.
Priority to CA002543133A priority Critical patent/CA2543133A1/en
Publication of CA2326804A1 publication Critical patent/CA2326804A1/en
Application granted granted Critical
Publication of CA2326804C publication Critical patent/CA2326804C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
CA002326804A 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors Expired - Fee Related CA2326804C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002543133A CA2543133A1 (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8013398P 1998-03-31 1998-03-31
US60/080,133 1998-03-31
PCT/US1999/007057 WO1999050247A1 (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002543133A Division CA2543133A1 (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors

Publications (2)

Publication Number Publication Date
CA2326804A1 true CA2326804A1 (en) 1999-10-07
CA2326804C CA2326804C (en) 2006-05-02

Family

ID=22155464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326804A Expired - Fee Related CA2326804C (en) 1998-03-31 1999-03-31 Compounds with activity on muscarinic receptors

Country Status (14)

Country Link
EP (1) EP1068185A1 (en)
JP (1) JP2002509918A (en)
KR (2) KR20060120715A (en)
CN (1) CN1303376A (en)
AR (1) AR014974A1 (en)
AU (1) AU762726B2 (en)
BR (1) BR9909277A (en)
CA (1) CA2326804C (en)
MX (1) MXPA00009569A (en)
NO (1) NO319835B1 (en)
NZ (2) NZ507204A (en)
RU (2) RU2230740C2 (en)
WO (1) WO1999050247A1 (en)
ZA (1) ZA200005149B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102997438A (en) * 2012-10-16 2013-03-27 李誊 Control method of electric water heater for improving heat utilization ratio

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
ES2251624T3 (en) 2001-12-28 2006-05-01 Acadia Pharmaceuticals Inc. ANALOGS OF TETRAHYDROQUINOLINE AS MUSCARINIC AGONISTS.
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
MXPA03000145A (en) 2002-01-07 2003-07-15 Pfizer Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators.
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2499494A1 (en) 2002-09-20 2004-04-01 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
DOP2003000703A (en) 2002-09-20 2004-03-31 Pfizer IMIDAZOPIRADINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
WO2005016276A2 (en) * 2003-08-05 2005-02-24 Samaritan Pharmaceuticals Inc. Sigma-1 receptor ligand with acetylcholinesterase inhibition properties
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MXPA06014486A (en) 2004-06-15 2007-03-01 Pfizer Benzimidazolone carboxylic acid derivatives.
ME02222B (en) 2004-12-30 2016-02-20 Janssen Pharmaceutica Nv Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP1939189A4 (en) 2005-08-26 2013-03-13 Shionogi & Co Derivative having ppar agonistic activity
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
CL2008000119A1 (en) 2007-01-16 2008-05-16 Wyeth Corp COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA.
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (en) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Novel piperazine salt and preparation method thereof
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
UA108233C2 (en) 2010-05-03 2015-04-10 Fatty acid amide hydrolysis activity modulators
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102558026A (en) * 2011-12-27 2012-07-11 盛世泰科生物医药技术(苏州)有限公司 Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1)
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN105073728A (en) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
CN105829310B (en) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 Bicyclic heterocycles and its therapeutical uses
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN111093662B (en) 2017-06-20 2023-10-03 安布里亚制药公司 Compositions and methods for improving cardiac metabolic efficiency
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695295A (en) * 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
GB874206A (en) * 1956-09-05 1961-08-02 Knoll Ag Basic derivatives of salicylamide
NL271658A (en) * 1960-12-01
FR1382425A (en) * 1963-01-14 1964-12-18 Ciba Geigy Process for preparing diaza-cyclo-alkanes, inter alia 3-methyl-4-phenyl-1- (2-phenylmercapto-ethyl) -piperazine
GB1053301A (en) * 1963-01-14
US3488352A (en) * 1966-10-11 1970-01-06 Shulton Inc Basically substituted alkoxy anthranilamides,their corresponding 2-nitro compounds and derivatives thereof
FR1543944A (en) * 1967-03-10 1968-10-31 Bruneau & Cie Lab Salicylic acid amide derivatives and their preparation
BE792187A (en) * 1971-12-03 1973-03-30 Sumitomo Chemical Co NEW ALKYLAMINE DERIVATIVES
DE2335432A1 (en) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-DIHYDRO-2H-NAPHTHALINONE- (1) 5-OXY-PROPYL-PIPERAZINE DERIVATIVES AND THE METHOD FOR THEIR PRODUCTION
GB1459506A (en) * 1974-02-18 1976-12-22 Wyeth John & Brother Ltd Piperidine derivatives
GB1498884A (en) * 1975-04-15 1978-01-25 Wyeth John & Brother Ltd Aminoacetamide-pyridyl-tetrahydropyridyl and-piperidyl derivatives
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
JP3390179B2 (en) * 1996-08-15 2003-03-24 シェーリング コーポレイション Ether muscarinic antagonist

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102997438A (en) * 2012-10-16 2013-03-27 李誊 Control method of electric water heater for improving heat utilization ratio

Also Published As

Publication number Publication date
WO1999050247A1 (en) 1999-10-07
NZ507204A (en) 2003-12-19
MXPA00009569A (en) 2002-08-06
EP1068185A1 (en) 2001-01-17
RU2004107218A (en) 2005-08-20
NO20004912D0 (en) 2000-09-29
KR100672186B1 (en) 2007-01-19
JP2002509918A (en) 2002-04-02
BR9909277A (en) 2001-10-16
KR20060120715A (en) 2006-11-27
ZA200005149B (en) 2002-01-08
CA2326804C (en) 2006-05-02
NO20004912L (en) 2000-11-23
AU762726B2 (en) 2003-07-03
RU2278111C2 (en) 2006-06-20
KR20010042248A (en) 2001-05-25
NO319835B1 (en) 2005-09-19
NZ525108A (en) 2005-02-25
AU3218799A (en) 1999-10-18
CN1303376A (en) 2001-07-11
AR014974A1 (en) 2001-04-11
RU2230740C2 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
CA2326804A1 (en) Compounds with activity on muscarinic receptors
WO2001005763A3 (en) Compounds with activity on muscarinic receptors
TW200505900A (en) Muscarinic agonists
BG104476A (en) Therapeutical form for tolterodin with controlled release
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
IL151164A0 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2375908A1 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
CA2274074A1 (en) Novel compounds with analgesic effect
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
CA2289717A1 (en) Novel therapy for constipation
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
CA2294921A1 (en) Levobupivacaine and its use
CA2158036A1 (en) 3,4-Diarylchromans for Treatment of Dermatitis
WO1997010824A8 (en) Use of 5ht1b receptor antagonist for the treatment of vascular disease
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
CA2356151A1 (en) Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
WO2003045942A3 (en) Chemokine receptor antagonists and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed